Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Clinical Trial of COVAC-2 in Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05209009
Recruitment Status : Not yet recruiting
First Posted : January 26, 2022
Last Update Posted : May 17, 2022
Sponsor:
Collaborators:
Government of Canada
Government of Saskatchewan
Vaccine Formulation Institute (VFI)
SEPPIC
Information provided by (Responsible Party):
Volker Gerdts, University of Saskatchewan

Brief Summary:

VIDO has developed a vaccine called COVAC-2.

The COVAC-2 study vaccine contains a portion of the SARS-CoV-2 spike protein, called S1. The spike protein is the part of the virus that is responsible for attaching to the surface of host cells. COVAC-2 contains a SWE adjuvant. An adjuvant is a compound that is added to a vaccine to help the vaccine produce a better immune response. The SWE adjuvant is similar to another adjuvant, MF59, that is found in influenza vaccines and MF59 containing vaccines have been given to millions of people around the world. The vaccine is expected to stimulate the body to make antibodies against the S1 protein. The antibodies will recognize the viral spike protein if the body is exposed to the virus and prevent severe COVID-19 illness. In animal studies, the immune response generated by the COVAC-2 vaccine was able to protect the vaccinated animals against a severe SARS-CoV-2 infection.

This is a Phase 2, placebo-controlled, observer-blind, age-stratified randomized, multicentre study to test the safety and immunogenicity of a dose level of the COVAC-2 vaccine (25 µg protein) administered twice (4 weeks apart) in generally healthy adults 18+ years of age. Up to 300 participants will be enrolled. For an individual participant, the duration of study will be approximately 12 months from the first vaccination (Day 0).


Condition or disease Intervention/treatment Phase
Severe Acute Respiratory Syndrome Coronavirus 2 Biological: COVAC-2 Biological: Saline Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Randomized, Observer-Blind, Dose-Escalation Phase 2 Clinical Trial of COVAC-2 in Generally Healthy Adults
Estimated Study Start Date : June 2022
Estimated Primary Completion Date : May 2023
Estimated Study Completion Date : August 2023


Arm Intervention/treatment
Experimental: Group A
COVAC-2 25 µg: 200 generally healthy adults > 18 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.
Biological: COVAC-2
Intramuscular vaccine against SARS-CoV-2

Placebo Comparator: Group B
100 generally healthy adults > 18 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of normal saline (placebo) on Day 28.
Biological: Saline Placebo
Intramuscular injection of saline placebo




Primary Outcome Measures :
  1. Assessment of the safety and tolerability of COVID-19 vaccine (COVAC-2) following two consecutive injections (28 days apart) in generally healthy volunteers [ Time Frame: Up to 365 days ]
    Incidence of solicited adverse events (AE) up to 7 days post-injection; unsolicited AEs up to 28 days post-injection; any clinically significant laboratory up to 28 days post-injection; and any serious AEs (SAEs), medically attended events (MAE), or Adverse Event of Special Interest (AESI) up to Day 365.


Secondary Outcome Measures :
  1. To assess the induction of SARS-CoV-2 spike protein (S) antibodies following two consecutive injections (28 days apart) of COVAC-2 vaccine through use of Enzyme-Linked immunosorbent Assay (ELISA) up to Day 365 [ Time Frame: Up to 365 days ]
    SARS-CoV-2 specific antibodies to Wuhan spike antigen or pseudovirus neutralizing antibodies pre- injection and post-injection as measured by spike protein-specific ELISA and serum neutralization assay.

  2. To assess SARS-CoV-2 spike protein-specific, cell-mediated response up to Day 365 induced by two consecutive injections (28 days apart) of COVAC-2 vaccine [ Time Frame: Up to 365 days ]
    Measurement of SARS-CoV-2 spike protein-specific, cell-mediated response markers in Peripheral Blood Mononuclear Cells (PBMCs) pre- and post-injection.


Other Outcome Measures:
  1. To assess the induction of SARS-CoV-2 Receptor Binding Domain (RBD) antibodies following two consecutive injections (28 days apart) of COVAC-2 vaccine through use of Enzyme-Linked immunosorbent Assay (ELISA) up to Day 365 [ Time Frame: Up to 365 days ]
    SARS-CoV-2 RBD antibodies collected pre- and post-injection as measured by RBD protein-specific ELISA.

  2. To evaluate the level of neutralizing antibody response against SARS-CoV-2 variants of concern (VOCs) up to Day 365 induced by two consecutive injections (28 days apart) of COVAC-2 vaccine [ Time Frame: Up to 365 days ]
    Neutralizing antibodies against SARS-CoV-2 VOCs pre- injection and post-injection as measured by serum neutralization assay.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Generally healthy male and female adults aged 18 years of age or older at the time of signing the informed consent form;
  2. Good general health as determined by screening evaluation not greater than 30 days before injection of first dose;

    Note: Participants who are overtly healthy as determined by medical evaluation or are considered medically stable according to the judgment of the investigator. A stable medical condition is defined as disease not requiring significant change in therapy or hospitalisation for worsening disease during the 3 months prior to enrolment, and/or hospitalization within the entire study period is not anticipated. Also, the participant appears likely to be able to remain in follow-up through the end of protocol-specified period. Mild to moderate well-controlled comorbidities are allowed.

  3. If female of child-bearing potential and heterosexually active, practice of adequate contraception for 30 days prior to injection, negative pregnancy test on the day of injection, and agreement to continue adequate contraception until 180 days after the second injection;
  4. Male participants are eligible to participate in the study if they agree to the following requirements during the study period and for at least 28 days after the last injection of study dose, i.e.,

    o Be abstinent from any heterosexual intercourse with a female of childbearing potential as their preferred and usual lifestyle.

    OR

    o Must agree to use a male condom when engaging in any activity that allows for passage of ejaculate to another person. In addition to male condom use, a highly effective method of contraception should be considered in women of child-bearing potential partners of male participants.

    AND

    o Must refrain from donating sperm; and

  5. Written informed consent, after review of the consent form and having adequate opportunity to discuss the study with an investigator or a qualified designee and pass the "Test of Understanding" (up to 3 attempts). For participants who cannot read or write, the consent must be witnessed by a literate third party not involved in study conduct.

Exclusion Criteria:

  1. Presence of any febrile illness or any known or suspected acute illness on the day of any immunization;
  2. Clinically significant bleeding disorder (e.g., clotting factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venipuncture.
  3. Any condition, which in the opinion of the Investigator, may make the participant inappropriate for the study;
  4. Receiving systemic immunosuppressive therapy or history of receiving chemotherapy in last 5 years other than topical agents;
  5. Receipt of systemic glucocorticoids (a dose ≥ 20 mg/day prednisone or equivalent for 14 days) within 1 month, or any other cytotoxic or immunosuppressive drug within 6 months;
  6. Cancer diagnosis in the last 5 years, excluding basal cell and squamous cell carcinoma of the skin, which are allowed;
  7. Presence of autoimmune disease;
  8. Receipt of any investigational drug within 6 months;
  9. Receipt of any non-COVID-19 authorized vaccines within 2 weeks of receiving study dose injection;
  10. Receipt of any authorized COVID-19 vaccine prior to study enrollment;
  11. Receipt of any other experimental SARS-CoV-2/COVID-19 or other experimental coronavirus vaccine(s) at any time prior to or during the study;
  12. Receipt of blood products or immunoglobulin (IVIg or IMIg) within 3 months of study entry/baseline serologic evaluation;
  13. Current anti-tuberculosis therapy;
  14. History of any reaction or hypersensitivity likely to be exacerbated by any component of the study vaccine;
  15. Hematologic or biochemical laboratory abnormalities (blood or urine), as defined by lab normal ranges. To exclude transient abnormalities, the investigator may repeat a test once, and if the repeat test is normal according to local reference ranges, participant may be enrolled. Grade 1 abnormalities of laboratory values will not be exclusionary if considered not clinically significant by the investigator; and
  16. Known current or previous laboratory-confirmed SARS-CoV-1 OR SARS-CoV-2 infection, as documented by a positive polymerase chain reaction (PCR) test from a nasal swab OR known or laboratory-confirmed positive serology.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05209009


Contacts
Layout table for location contacts
Contact: Geofrey Kimbugwe, Dr. 2560417704191 geofrey.kimbugwe@mrcuganda.org
Contact: Juliet Mwanga 256761001355 juliet.mwanga@epicentre.msf.org

Sponsors and Collaborators
University of Saskatchewan
Government of Canada
Government of Saskatchewan
Vaccine Formulation Institute (VFI)
SEPPIC
Layout table for additonal information
Responsible Party: Volker Gerdts, Director & CEO, University of Saskatchewan
ClinicalTrials.gov Identifier: NCT05209009    
Other Study ID Numbers: COVAC-003
First Posted: January 26, 2022    Key Record Dates
Last Update Posted: May 17, 2022
Last Verified: May 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Severe Acute Respiratory Syndrome
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Virus Diseases
Infections
Respiratory Tract Infections
Respiratory Tract Diseases